key: cord-0967371-6683ezfx
authors: Yang, Qian; Jiang, Qi; Niu, Man Man; Fan, Guo Zhen; Hu, Peng
title: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated
date: 2022-03-29
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2022.02.070
sha: ba9aab413d555fb656f0ee05c1b58d00a188ef86
doc_id: 967371
cord_uid: 6683ezfx

nan

The authors presented data of 7,361 patients with immune-mediated inflammatory diseases(IMID) 26 treated with immunosuppressive biologics and 74,910 matched controls, and found that patients 27 receiving TNF inhibitors were less likely to be diagnosed with SARS-CoV-2 infection compared to matched 28 controls, whereas overall, biologics did not increase the risk of positive COVID-19 diagnosis, adjusting for 29 demographics, comorbidity burden and local infection rates. According to the patient baseline 30 characteristics listed in Table 1 

Immunosuppressive biologics did not increase the risk of 70 COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts

SARS-CoV-2 vaccination in rituximab-treated patients: B cells 73 promote humoral immune responses in the presence of T-cell-mediated immunity

Humoral and cellular responses to mRNA vaccines against 76 SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-77 initiated, single-centre, open-label study

Antibody response to COVID-19 booster vaccine in rituximab-treated 80 patients with anti-neutrophil cytoplasmic antibody-associatedvasculitis

Efficacy and safety of SARS-CoV-2 revaccination in non-responders 83 with immune-mediated inflammatory disease